ABSTRACT
Background:
IL-17 antagonists are a new class of biologic agents consisting of antibodies against IL-17A and its receptor. Three biologic agents belong to this novel category: Secukinumab, ixekizumab and brodalumab. These new agents are highly effective for treatment of moderate to severe psoriasis leading to complete or almost complete clearance of psoriatic lesions in a substantial proportion of patients. Results reported on the safety of IL-17 antagonists are also promising.
